Clinical Trial Update: Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating osimertinib in combination with alisertib or sapanisertib for osimertinib-resistant EGFR-mutant stage IIIB/IV non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alisertib (MLN8237) (alisertib)
• Osimertinib (Tagrisso) (osimertinib)
• Sapanisertib (MLN0128) (sapanisertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 1 | Status: COMPLETED